People · Operator
Named in public records as an officer, director or promoter · active 2011–2025 · Other, Biotechnology, Other Technology, Retailing, Agtech / Foodtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Miyoko's, PBC | — | Other | Series C | $65.4M | $16.3M | 2021 |
| Numi, Inc. | — | Other | Series B | $34.7M | $265.8M | 2013 |
| MycoMedica Life Sciences, PBC | — | Biotechnology | Series B | $29.9M | $606.9M | 2021 |
| Nectar Life Sciences, Inc. | — | Other Technology | Series B | $24.3M | $320.2M | 2022 |
| Nest Collective, Inc. | — | Other | Series B | $22.0M | $99.7M | 2011 |
| Well Found, Inc. | — | Retailing | Series A | $12.4M | $30.9M | 2025 |
| Pixable Inc. | — | Other | Seed | $9.3M | $66.8M | 2011 |
| Breezeworks Corp | — | Other Technology | Series A | $5.1M | $142.3M | 2014 |
| Birrbit Inc | — | Other Technology | Series A | $4.6M | $118.6M | 2011 |
| All in Food PBC | — | Agtech / Foodtech | Seed | $4.0M | $14.4M | 2024 |
James Joaquin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Joaquin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jed Smith | 2 | 8 |
| Sheryl O'Loughlin | 2 | 3 |
| Robert Davis | 1 | 17 |
| James Harris | 1 | 10 |
| Curtis Mo | 1 | 8 |
| Matthew Cowan | 1 | 7 |
| John Kenney | 1 | 5 |
| AHMED RAHIM | 1 | 4 |
| Jon Owsley | 1 | 4 |
| Ilya Nykin | 1 | 4 |
| Tad Buchanan | 1 | 4 |
| Todd Steele | 1 | 3 |
| Neil Grimmer | 1 | 3 |
| Michael Meyer | 1 | 3 |
| LISA FERIA | 1 | 3 |
| Patrick Chun | 1 | 3 |
| Neil Blomquist | 1 | 2 |
| John Mecklenburg | 1 | 2 |
| Martin Fogelman | 1 | 2 |
| Miyoko Schinner | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.